Please login to the form below

Not currently logged in

WCCT Global talks up orphan drug benefits of new service

CRO's In-Site programme will harness digital technology for patient recruitment

WCCT GlobalContract research organisation WCCT Global says its newly-launched patient recruitment service could have particular application in orphan drug trials.

The California, US-based CRO's new In-Site programme uses digital technology to locate patient groups and determine the best sites to conduct the clinical trial.

WCCT says patient recruitment is often as much of a challenge as the technical and commercial hurdles orphan drugs face, if not more so. 

WCCT Global's chief operating officer Jon Rojas said: "We have established our specialised recruitment method which is uniquely applicable to the recruitment issues faced by sponsors that are developing orphan drugs. We point this out because we feel there is a need in the clinical research industry that must to be filled.”

The In-Site patient recruitment tool focuses on identifying patients that could best fit a particular trial to increase the efficiency of the process. 

The new programme also includes an “advanced digital advertising process”. This entails creating an “in-depth psychographic” based on the orphan indication and then targeting digital and social media outlets in order to ensure patient access.

Article by
Dominic Tyer

26th February 2014

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
FCB Halesway

A Eureka moment! A converted dairy in the Hampshire countryside back in 1993 saw the inception of Halesway as a...

Latest intelligence

Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...